ADC Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Common SharesBusiness Wire • 10/09/20
ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaBusiness Wire • 09/21/20
ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020Business Wire • 09/17/20
ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor CancersBusiness Wire • 09/10/20
ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131Business Wire • 09/05/20
ADC Therapeutics SA (ADCT) CEO Christopher Martin on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/19/20
ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business HighlightsBusiness Wire • 08/18/20
ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020Business Wire • 08/12/20
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With IbrutinibBusiness Wire • 07/17/20
ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab TesirineBusiness Wire • 07/06/20